CLINICAL TRIALS PROFILE FOR AXITINIB

505(b)(2) Clinical Trials for axitinib

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
New Combination	NCT03571438 ↗	Evaluation of a Promising New Combination of Protein Kinase Inhibitors on Organotypic Cultures of Human Renal Tumors	Recruiting	University Hospital, Grenoble	N/A	2017-10-16	The investigators objective is to test the combination directly on organotypic cultures of tumors from patients after their excision in the Department of Urology and Renal Transplantation of the University Hospital of Grenoble and to compare their efficacy with that of currently selected treatments in the clinic. The population targeted by the combination for use in clinical practice is patients with metastatic clear cell renal cell carcinoma. Current treatments for these patients are Sunitinib, Pazopanib and Temsirolimus.
New Combination	NCT05070221 ↗	Study of Oncolytic Virus in Combination With HX-008 and Axitinib in Melanoma Patients With Liver Metastasis	Not yet recruiting	Beijing Cancer Hospital	Phase 1	2021-10-01	Malignant melanoma, is a kind of malignant tumor derived from melanocytes. It is common in skin, mucous membrane, eye choroid and other parts. Melanoma is one of the fastest growing malignant tumors with an annual incidence rate of 3-5%. In 2012, there were 232000 new cases of melanoma and 55000 deaths worldwide. Though, the incidence rate of melanoma is relatively low in China, it has been increasing rapidly in recent years. Melanoma has seriously endangering the health of Chinese people. Patients with stage Ⅳ melanoma have a poor prognosis. According to statistics, the median survival time of stage M1a melanoma is 15 months, while stage M1b is 8 months. The median survival time of bone metastasis melanoma is 6 months, while liver and brain metastasis is 4 months. The overall median survival time of metastatic melanoma is only 7.5 months, and the 2-year survival rate is 15%. For patients with advanced melanoma, dacarbazine is the only chemotherapy drug approved by NMPA, but its overall effective rate is only 13.4%, and the median survival time is 5.6 ~ 11 months. Therapies(new drugs or new combination treatments)with higher remission rate and longer survival are urgently needed for patients with advanced melanoma.
New Combination	NCT07159191 ↗	Envafolimab Combined With Axitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma	NOT_YET_RECRUITING	Peking Union Medical College Hospital	PHASE2	2025-09-01	Introduction: This document explains a clinical research study conducted at Peking Union Medical College Hospital. The study aims to evaluate a new combination treatment - Envafolimab (an immunotherapy) and Axitinib (a targeted therapy) - for patients newly diagnosed with advanced kidney cancer (specifically, clear cell Renal Cell Carcinoma or RCC). This information is designed to help patients, their families, and healthcare providers understand the study's purpose, procedures, potential benefits and risks, and what participation involves. 1. What is the Study About? * The Problem: Advanced kidney cancer (RCC) that has spread (metastatic) or cannot be removed by surgery (unresectable) is challenging to treat. While treatments exist, researchers are always looking for more effective and manageable options, especially for patients who haven't had prior systemic (whole-body) anti-cancer therapy. * The New Approach: This study combines two types of drugs: * Envafolimab: An "immunotherapy" drug given as an injection under the skin (subcutaneous). It works by blocking a protein called PD-L1 on cancer cells or immune cells. Blocking PD-L1 helps the patient's own immune system recognize and attack the cancer cells more effectively. * Axitinib: A "targeted therapy" drug taken as a pill twice daily. It works by blocking signals (VEGF receptors) that cancer cells use to grow new blood vessels, essentially starving the tumor of its blood supply. * The Goal: To find out if giving Envafolimab and Axitinib together is safe and effective as the first treatment for patients with advanced kidney cancer. Researchers want to see how well the combination shrinks tumors, controls the cancer, and how long patients live without their cancer getting worse, while carefully monitoring side effects. * Study Design: * Phase II: This is an early stage of testing in patients, focusing mainly on how well the treatment works and its safety profile in a specific group. * Single-Arm: All participants in this study will receive the same combination treatment (Envafolimab + Axitinib). There is no separate group receiving a different treatment or placebo for comparison in this particular study. * Single-Center: Currently being run at Peking Union Medical College Hospital (but could potentially expand). * Participants: Plans to enroll about 30 patients. * Treatment Duration: Patients receive treatment as long as it's working (tumor isn't growing) and they can tolerate the side effects, for up to a maximum of 2 years. 2. Key Information for Patients \& Families: * Who Might Qualify? You may be eligible to participate if you: * Are between 18 and 75 years old. * Have been diagnosed with advanced clear cell kidney cancer (unresectable or metastatic). * Have NOT received any prior systemic anti-cancer treatment (like chemotherapy, immunotherapy, or other targeted therapies) for your advanced kidney cancer. * Have tumors that can be measured on scans (CT or MRI). * Are relatively active and able to care for yourself (ECOG performance status 0 or 1: meaning you are either fully active or restricted in physically strenuous activity but ambulatory and able to do light work). * Have adequate organ function (healthy enough bone marrow, liver, kidneys, heart) as determined by blood tests. * Are expected to live at least 6 more months. * Understand the study and agree to follow the procedures and attend all visits. * Who Would Not Qualify? You would likely not be eligible if you: * Have another active cancer besides the kidney cancer being studied. * Have had previous systemic treatment for your advanced kidney cancer. * Have known severe allergies to similar drugs or components of Envafolimab/Axitinib. * Have an active autoimmune disease needing strong medication (like high-dose steroids or immunosuppressants) within the last 2 years. (Hormone replacements like thyroid meds are okay). * Are taking high-dose steroids (except inhaled/nasal) or other immune-suppressing drugs shortly before starting. * Are using traditional Chinese medicine or immunomodulators within 2 weeks before joining. * Have serious uncontrolled heart problems (like recent heart attack, severe heart failure, unstable angina, significant irregular heartbeats). * Have uncontrolled fluid build-up needing drainage (like large amounts of ascites or pleural effusion). * Are pregnant, breastfeeding, or unwilling to use highly effective contraception during the study and for 6 months after. * Have significant psychiatric, substance abuse, or other medical/social issues that the research team believes would interfere with the study.

All Clinical Trials for axitinib

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00071006 ↗	AG-013736 (Axitinib) In Patients With Poor Prognosis Acute Myeloid Leukemia (AML) Or Myelodysplastic Syndrome (MDS)	Completed	Pfizer	Phase 2	2003-09-01	The study tests the safety and efficacy of axitinib in patients who have the hematologic disease of Acute Myeloid Leukemia or Myelodysplastic Syndrome. The study tests patients who have poor prognosis before entering the study.
NCT00094094 ↗	Anti-angiogenesis Agent AG-013736 in Patients With Advanced Non-Small Cell Lung Cancer	Completed	Pfizer	Phase 2	2005-02-01	This is a Phase 2 study being conducted at multiple centers in the United States and Germany. Patients having non-small cell lung cancer that has spread to other parts of the body (i.e., metastatic) or is locally advanced (i.e., Stage IIIB with malignant pleural effusion) are eligible to participate. Patients must have disease that has been treated with at least 1 prior treatment for metastatic disease (prior adjuvant treatment for localized disease does not count as prior treatment for metastatic disease). The purpose of the study is to test whether the angiogenesis inhibitor AG-013736 is an effective treatment for advanced non-small cell lung cancer as shown by the number of patients in the study who experience significant and durable tumor shrinkage
NCT00219557 ↗	AG-013736 In Combination With Gemcitabine Versus Gemcitabine Alone For Patients With Metastatic Pancreatic Cancer	Completed	Pfizer	Phase 2	2005-07-05	This is a Phase 2 study being conducted at multiple centers in the United States, Europe and Canada. Patients having pancreatic cancer that is locally advanced or that has spread to other parts of the body (i.e., metastatic) are eligible to participate. Patients must have not had any prior systemic treatment for advanced disease. The purpose of the study is to test whether the angiogenesis inhibitor Axitinib [AG-013736] in combination with gemcitabine is an effective treatment for advanced pancreatic cancer vs. gemcitabine alone by overall survival.
NCT00447005 ↗	Study Of AG-013736 (Axitinib) In Patients With Advanced Solid Tumors	Completed	Pfizer	Phase 1	2007-02-01	To evaluate the clinically recommended dose of AG-013736 (Axitinib) in Japanese patients by reviewing the safety of AG-013736 (Axitinib) following single and multiple dosing.
NCT00471146 ↗	Study Of Gemcitabine Plus AG-013736 Versus Gemcitabine For Advanced Pancreatic Cancer.	Completed	Pfizer	Phase 3	2007-07-01	The purpose of this study is to determine whether investigational study drug, AG-013736, and gemcitabine are effective in the first-line treatment of advanced pancreatic cancer.
NCT00569946 ↗	Study Of AG-013736 (Axitinib) As Second-Line Treatment In Patients With Metastatic Renal Cell Cancer (mRCC)	Completed	Pfizer	Phase 2	2007-12-12	To investigate objective tumor response of AG-013736 for metastatic Renal Cell Cancer (mRCC)
NCT00600821 ↗	A Study Of AG-013736 (Axitinib) Or Bevacizumab (Avastin) In Combination With Paclitaxel And Carboplatin In Patients With Advanced Lung Cancer.	Completed	Pfizer	Phase 2	2008-04-01	To determine if the addition of AG-013736 to chemotherapy is beneficial in patients with advanced lung cancer who have not been previously treated.

Clinical Trial Conditions for axitinib

Condition Name

Condition Name for axitinib
Intervention	Trials
Renal Cell Carcinoma	19
Clear Cell Renal Cell Carcinoma	12
Metastatic Renal Cell Carcinoma	11
Carcinoma, Renal Cell	7

Condition MeSH

Condition MeSH for axitinib
Intervention	Trials
Carcinoma, Renal Cell	74
Carcinoma	59
Kidney Neoplasms	17
Neoplasms	12

Clinical Trial Locations for axitinib

Trials by Country

Trials by Country for axitinib
Location	Trials
United States	552
Japan	66
China	44
United Kingdom	39
Canada	34

Trials by US State

Trials by US State for axitinib
Location	Trials
California	34
Texas	33
New York	28
Ohio	26
Florida	25

Clinical Trial Progress for axitinib

Clinical Trial Phase

Clinical Trial Phase for axitinib
Clinical Trial Phase	Trials
PHASE4	1
PHASE3	4
PHASE2	11

Clinical Trial Status

Clinical Trial Status for axitinib
Clinical Trial Phase	Trials
Completed	60
Recruiting	50
Not yet recruiting	23

Clinical Trial Sponsors for axitinib

Sponsor Name

Sponsor Name for axitinib
Sponsor	Trials
Pfizer	77
National Cancer Institute (NCI)	14
Merck Sharp & Dohme Corp.	8

Sponsor Type

Sponsor Type for axitinib
Sponsor	Trials
Other	151
Industry	143
NIH	14

Axitinib Clinical Trials, Market Analysis, Patent Exclusivity and 2025-2030 Outlook

Last updated: August 1, 2026

Axitinib is Pfizer’s oral VEGFR tyrosine kinase inhibitor marketed as Inlyta for advanced renal cell carcinoma (RCC). Its commercial position rests on two FDA-approved combinations: axitinib plus pembrolizumab and axitinib plus avelumab. The monotherapy market is mature, while combination therapy remains clinically relevant in first-line clear-cell RCC.

The principal commercial risk is U.S. loss of composition-of-matter exclusivity in 2025, subject to patent-term adjustment, pediatric exclusivity, Orange Book listings, and the timing of ANDA approvals. Pfizer’s strongest defense is the clinical value of the combinations, but pembrolizumab and avelumab themselves are not protected from substitution by axitinib patents.

What is axitinib and how is it used?

Axitinib is a selective inhibitor of VEGFR-1, VEGFR-2, and VEGFR-3. It is administered orally and has a short plasma half-life, allowing dose modification based on tolerability and blood-pressure control.

Attribute	Axitinib
Brand	Inlyta
Active ingredient	Axitinib
Developer and marketer	Pfizer
Drug class	VEGFR tyrosine kinase inhibitor
FDA approval	2012
Primary indication	Advanced renal cell carcinoma
Monotherapy dose	Typically 5 mg twice daily
Combination use	Pembrolizumab or avelumab
Dosage form	Immediate-release tablets
Main safety risks	Hypertension, diarrhea, fatigue, palmar-plantar erythrodysesthesia, hepatotoxicity, arterial and venous thromboembolism

The original FDA approval covered patients with advanced RCC after failure of one prior systemic therapy. The label later expanded to first-line treatment in combination with immune checkpoint inhibitors.

What FDA approvals does axitinib have?

Axitinib has three principal U.S. use settings:

FDA-approved regimen	Approval timing	Clinical setting
Axitinib monotherapy	2012	Advanced RCC after one prior systemic therapy
Axitinib plus avelumab	2019	First-line advanced RCC
Axitinib plus pembrolizumab	2019	First-line advanced RCC

The pembrolizumab combination was supported by KEYNOTE-426, a randomized Phase 3 study in previously untreated advanced RCC. The regimen improved overall survival, progression-free survival, and objective response rate against sunitinib in the initial analysis (Rini et al., 2019).

The avelumab combination was supported by JAVELIN Renal 101. The study improved progression-free survival in the PD-L1-positive population and in the intention-to-treat population, although subsequent overall-survival interpretation was affected by extensive crossover and later treatment patterns (Motzer et al., 2019).

What clinical trials are evaluating axitinib?

KEYNOTE-426: axitinib plus pembrolizumab

KEYNOTE-426, listed as NCT02853331, established axitinib plus pembrolizumab as a first-line regimen for advanced clear-cell RCC. Long-term follow-up continued to show a survival advantage versus sunitinib, although treatment selection has become more complex as nivolumab-plus-ipilimumab and nivolumab-plus-cabozantinib entered the same market.

The regimen’s commercial advantage is strongest in patients for whom a VEGF-directed agent plus PD-1 therapy is preferred. Its limitations include hypertension, diarrhea, liver-enzyme abnormalities, immune-related adverse events from pembrolizumab, and the cost of combination treatment.

JAVELIN Renal 101: axitinib plus avelumab

JAVELIN Renal 101, listed as NCT02684006, evaluated axitinib plus avelumab against sunitinib. The regimen received FDA approval in 2019. Commercial uptake has been weaker than that of pembrolizumab plus axitinib because avelumab has had less momentum in RCC treatment algorithms and because competing regimens have produced stronger physician preference.

Adjuvant and earlier-stage RCC research

Axitinib has been tested in earlier-stage and adjuvant RCC settings. The ATLAS study, listed as NCT01599754, evaluated adjuvant axitinib after nephrectomy. It did not establish a new standard of care. The negative or inconclusive adjuvant experience limits axitinib’s expansion beyond advanced disease.

Combination and sequencing research

Clinical research has examined axitinib with checkpoint inhibitors, other antiangiogenic agents, and treatment sequences after immunotherapy. The most commercially relevant development path remains combination therapy rather than a new axitinib monotherapy indication.

How does axitinib compare with competing RCC drugs?

Axitinib competes with VEGF-TKIs, immune checkpoint inhibitors, and combination regimens.

Regimen	Main sponsor	Market position	Competitive assessment
Axitinib plus pembrolizumab	Pfizer and Merck	First-line advanced RCC	Strong evidence and broad clinical use
Axitinib plus avelumab	Pfizer and Merck KGaA	First-line advanced RCC	Approved but commercially less dominant
Nivolumab plus ipilimumab	Bristol Myers Squibb	First-line advanced RCC	Strong durable-response profile
Nivolumab plus cabozantinib	Bristol Myers Squibb and Exelixis	First-line advanced RCC	Broad efficacy and active post-immunotherapy positioning
Pembrolizumab plus lenvatinib	Merck and Eisai	First-line advanced RCC	Strong efficacy, with tolerability and dosing considerations
Cabozantinib monotherapy	Exelixis	Later-line and selected first-line use	Strong post-immunotherapy positioning
Pazopanib and sunitinib	Novartis and Pfizer, respectively	Established VEGF-TKI alternatives	Older agents with lower differentiation

Axitinib’s pharmacologic differentiation is its VEGFR selectivity and short half-life, which can support titration and rapid dose reduction. Its disadvantages are dependence on combination partners, substantial hypertension risk, and exposure to generic erosion.

What patents protect axitinib and Inlyta?

Axitinib’s central U.S. patent estate is associated with composition-of-matter protection and related pharmaceutical claims. The key patent commonly cited for axitinib is U.S. Patent No. 7,982,028.

Patent or protection	Subject matter	Reported relevance
U.S. Patent No. 7,982,028	Axitinib compound and related pharmaceutical claims	Core composition protection
Orange Book-listed patents	Product, formulation, or method claims, depending on listing	Potential ANDA litigation basis
Pediatric exclusivity	Regulatory exclusivity attached to qualifying patents	May extend enforceable protection beyond patent expiry

Public patent databases and FDA Orange Book records should be used together because patent listings, expiration dates, patent-term adjustment, and pediatric exclusivity can differ by jurisdiction and regulatory update.

The commercially important date is the effective U.S. generic-entry date, not the nominal expiration date alone. A generic applicant may receive tentative approval before patent expiry but cannot market until the relevant patents and regulatory exclusivities no longer block launch.

When does axitinib lose exclusivity?

Axitinib’s core U.S. composition patent is generally reported to expire in 2025, before any potential six-month pediatric extension. The effective date for unrestricted generic marketing depends on:

1. Patent-term adjustment and any terminal disclaimer.
2. Orange Book-listed patents.
3. Pediatric exclusivity.
4. Paragraph IV litigation.
5. The timing of FDA approval of ANDAs.
6. Settlement agreements or authorized-generic arrangements.

The practical base case is U.S. generic entry around the 2025-2026 period if an ANDA applicant clears litigation and regulatory requirements. Earlier entry could occur through a settlement, license, or authorized generic. Later entry could result from patent litigation or additional enforceable listings.

What is the Orange Book status of Inlyta?

FDA’s Orange Book is the controlling source for approved products, reference-product designations, listed patents, and patent-expiration information. Inlyta is listed as the reference product for axitinib tablets.

Axitinib is particularly exposed to ANDA competition because:

• It is a small-molecule oral product.
• It uses an immediate-release tablet dosage form.
• Bioequivalence can generally be demonstrated through conventional ANDA standards.
• The product has no biologic or biosimilar barrier.
• The major commercial indication does not require a complex delivery system.

Method-of-use patents covering RCC treatment may delay or complicate approval if an ANDA applicant uses a section viii carve-out. Such patents do not necessarily block approval for all indications, but they can limit the labeling available to the generic applicant.

Which companies are challenging axitinib exclusivity?

Axitinib generic competition is expected to come from established generic manufacturers with oncology portfolios, including companies such as Teva, Sandoz, Dr. Reddy’s Laboratories, Sun Pharma, Cipla, Zydus, and Accord. The identity and status of individual applicants should be confirmed through FDA ANDA records and Paragraph IV litigation filings.

The main litigation venue is the U.S. District Court for the District of Delaware, although Hatch-Waxman cases can also be filed in other federal districts. A Paragraph IV notice alleging that a listed patent is invalid, unenforceable, or not infringed typically gives the brand company 45 days to file suit. A timely suit can trigger a 30-month stay of FDA approval, subject to statutory exceptions.

What patent litigation affects axitinib?

Axitinib litigation risk is concentrated around the core compound patent and any Orange Book-listed formulation or method-of-use claims. The most important events are:

Event	Business impact
Paragraph IV notice	Signals potential first-filer or early generic challenge
Brand patent suit	Can impose a 30-month approval stay
Claim construction and validity rulings	Determine whether early entry remains possible
Settlement or license	Can establish a negotiated launch date
FDA approval of ANDA	Does not itself guarantee immediate commercial launch
Authorized-generic agreement	Can reduce Pfizer’s volume loss but pressure net price

A settlement can preserve branded pricing longer than open litigation but may create an earlier defined generic-entry date. The economic outcome depends on whether the challenger receives first-filer exclusivity and whether multiple manufacturers launch simultaneously.

What generic launch scenarios exist for axitinib?

Scenario 1: Delayed single-generic entry

One applicant launches after patent expiry or a negotiated settlement. Price erosion is gradual, and Pfizer retains a meaningful share through brand loyalty and combination prescribing.

Scenario 2: First-filer launch followed by rapid competition

A Paragraph IV challenger launches after litigation or settlement, then additional ANDA holders enter. Net prices decline rapidly as pharmacy and payer substitution increases.

Scenario 3: Authorized generic

Pfizer licenses or supplies an authorized generic. This can protect part of the molecule’s economics but usually accelerates payer switching and reduces the branded product’s net price.

Scenario 4: Carve-out-driven entry

A generic launches with selected indications or without certain patented methods of use. Pharmacy substitution and payer policies determine whether the carve-out materially limits uptake.

How strong is the axitinib patent estate?

Axitinib has a moderate-to-weak late-life patent position relative to newer oncology products. Its strength is concentrated in the original small-molecule patent rather than in a broad platform estate.

Patent-estate factor	Assessment
Core compound protection	Historically strong, but near expiry
Formulation differentiation	Limited for an immediate-release tablet
Device protection	Not a major barrier
Manufacturing complexity	Moderate, not biologic-level
Method-of-use breadth	Potentially useful but vulnerable to carve-outs
Biosimilar protection	Not applicable
Lifecycle-management potential	Limited compared with biologics

Manufacturing is unlikely to create a durable barrier after composition protection expires. Axitinib is a chemically defined small molecule, and generic manufacturers can use conventional solid-dose manufacturing once regulatory and patent barriers are cleared.

What is the axitinib market outlook through 2030?

Axitinib sales are likely to decline after generic entry, but the rate depends on the timing and number of launches. Combination use with pembrolizumab does not prevent substitution of axitinib because the two products are separately dispensed and separately reimbursed.

Period	Expected commercial condition
2024	Branded product supported by approved combination regimens
2025	Core U.S. patent-exclusivity transition
2026	Highest probability of material U.S. generic pressure
2027-2028	Multiple-generic price erosion likely
2029-2030	Mature generic market; brand sales concentrated in protected channels and selected international markets

A reasonable planning framework is:

• Before generic entry: stable or modestly declining branded revenue.
• First year after entry: 30% to 60% U.S. unit displacement, depending on the number of entrants and payer substitution.
• Mature multi-generic phase: 70% to 90% branded revenue erosion in the U.S. is possible for an oral small molecule.
• International erosion: slower in markets with separate patent dates, tender systems, or delayed generic approvals.

These are scenario ranges rather than company guidance. The largest variables are the actual launch date, first-filer status, litigation outcomes, and Pfizer’s pricing response.

What licensing deals affect axitinib?

Pfizer is the principal commercial rights holder for Inlyta. Axitinib originated from Sugen, a company acquired by Pharmacia, which was later acquired by Pfizer. No major current third-party licensing arrangement is central to the product’s global commercial strategy.

The more important economic relationship is the combination with pembrolizumab, marketed by Merck, and with avelumab, marketed through the Pfizer and Merck KGaA collaboration. Those arrangements affect commercial positioning but do not transfer axitinib patent ownership.

What is the regulatory status of axitinib outside the United States?

Axitinib is approved in multiple major markets for advanced RCC, including the European Union and Japan, subject to local labeling and combination indications. Patent expiry and generic approval dates differ by country.

Geographic risk is therefore uneven:

• United States: highest near-term exposure because of the expected 2025-2026 exclusivity transition.
• European Union: country-specific launch timing and national reimbursement decisions.
• Japan: local patent and regulatory timing can delay substitution.
• Emerging markets: earlier generic competition may occur where patent enforcement is weaker or absent.
• China and other regulated markets: local registration, patent linkage, and procurement rules affect launch timing.

Key Takeaways

• Axitinib is a mature oral VEGFR inhibitor with continuing relevance in first-line RCC combinations.
• Pembrolizumab plus axitinib is the product’s strongest clinical and commercial franchise.
• Avelumab plus axitinib remains FDA-approved but has weaker competitive momentum.
• U.S. core composition protection is generally reported to expire in 2025, with effective entry potentially extending into 2026.
• Axitinib has no biosimilar barrier because it is a small molecule.
• Immediate-release tablets are relatively accessible to ANDA manufacturers.
• Generic entry could reduce U.S. branded revenue by 70% to 90% after a mature multi-generic launch.
• The decisive variables are Orange Book listings, Paragraph IV litigation, settlement terms, first-filer status, and FDA ANDA approvals.

FAQs

Does pembrolizumab patent protection prevent generic axitinib substitution?

No. Pembrolizumab and axitinib are separate products. A generic axitinib can be substituted for branded axitinib where allowed, even if pembrolizumab remains patent-protected.

Is axitinib a biologic or a biosimilar product?

No. Axitinib is a chemically synthesized small molecule. Generic competition proceeds through the ANDA pathway, not the biosimilar pathway.

Can generic axitinib be approved for every RCC indication?

Not necessarily. An ANDA applicant may use a section viii labeling carve-out for patented methods of use. The approved generic label may initially exclude selected indications or dosing instructions.

Does axitinib have orphan-drug exclusivity?

Axitinib’s principal commercial protection has come from patents and standard regulatory exclusivities rather than a durable orphan-drug exclusivity strategy.

Which RCC regimen most directly competes with axitinib plus pembrolizumab?

The closest alternatives are nivolumab plus cabozantinib, pembrolizumab plus lenvatinib, and nivolumab plus ipilimumab. Treatment selection depends on efficacy, toxicity, prior immunotherapy, physician preference, and payer policy.

References

1. U.S. Food and Drug Administration. (2012). FDA approves Inlyta for advanced kidney cancer.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. U.S. Food and Drug Administration. (2024). Inlyta prescribing information. Pfizer Laboratories.
4. Motzer, R. J., Penkov, K., Haanen, J., et al. (2019). Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. New England Journal of Medicine, 380(12), 1103-1115.
5. Rini, B. I., Plimack, E. R., Stus, V., et al. (2019). Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. New England Journal of Medicine, 380(12), 1116-1127.
6. National Library of Medicine. (2024). ClinicalTrials.gov: NCT02853331, NCT02684006, and NCT01599754.
7. U.S. Patent and Trademark Office. (2011). U.S. Patent No. 7,982,028: Pyrimidine compounds and methods of use.